✦ LIBER ✦

ND1 COST-EFFECTIVENESS OF DISEASE-MODIFYING THERAPY FOR MULTIPLE SCLEROSIS: A POPULATION-BASED EVALUATION

✍ Scribed by K Noyes; A Bajorska; AR Chappel; S Schwid; LR Mehta; R Holloway; A Dick

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-Effectiveness of Disease-Modifying

✍ Paul Tappenden; Christopher McCabe; Jim Chilcott; Emma Simpson; Richard Nixon; J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB

PND45 USE OF DISEASE-MODIFYING DRUGS IN

✍ K Noyes; A Bajorska; S Schwid; R Holloway; A Dick 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

A health-economic evaluation of disease-

✍ Mark Nuijten; Thomas Mittendorf 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 156 KB

Cost-effectiveness of losartan-based the

✍ McInnes, G; Burke, T A; Carides, G 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB